Cargando…

Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort

The immune response in patients with Coronavirus Disease 2019 (COVID-19) is highly variable and is linked to disease severity and mortality. However, antibody and cytokine responses in the early disease stage and their association with disease course and outcome are still not completely understood....

Descripción completa

Detalles Bibliográficos
Autores principales: Ruytinx, Pieter, Vandormael, Patrick, Fraussen, Judith, Pieters, Zoë, Thonissen, Stef, Hellings, Niels, Stinissen, Piet, Callebaut, Ina, Penders, Joris, Vanhove, Karolien, Kieffer, Davy, Rummens, Jean-Luc, Valkenborgh, Tom, Messiaen, Peter, Stessel, Björn, Mesotten, Dieter, Somers, Veerle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630327/
https://www.ncbi.nlm.nih.gov/pubmed/37935729
http://dx.doi.org/10.1038/s41598-023-46421-4
_version_ 1785132126215077888
author Ruytinx, Pieter
Vandormael, Patrick
Fraussen, Judith
Pieters, Zoë
Thonissen, Stef
Hellings, Niels
Stinissen, Piet
Callebaut, Ina
Penders, Joris
Vanhove, Karolien
Kieffer, Davy
Rummens, Jean-Luc
Valkenborgh, Tom
Messiaen, Peter
Stessel, Björn
Mesotten, Dieter
Somers, Veerle
author_facet Ruytinx, Pieter
Vandormael, Patrick
Fraussen, Judith
Pieters, Zoë
Thonissen, Stef
Hellings, Niels
Stinissen, Piet
Callebaut, Ina
Penders, Joris
Vanhove, Karolien
Kieffer, Davy
Rummens, Jean-Luc
Valkenborgh, Tom
Messiaen, Peter
Stessel, Björn
Mesotten, Dieter
Somers, Veerle
author_sort Ruytinx, Pieter
collection PubMed
description The immune response in patients with Coronavirus Disease 2019 (COVID-19) is highly variable and is linked to disease severity and mortality. However, antibody and cytokine responses in the early disease stage and their association with disease course and outcome are still not completely understood. In this large, multi-centre cohort study, blood samples of 434 Belgian COVID-19 hospitalized patients with different disease severities (ranging from asymptomatic/mild to critically ill) from the first wave of the COVID-19 pandemic were obtained. Baseline antibody and cytokine responses were characterized and associations with several clinical outcome parameters were determined. Anti-spike immunoglobulin (Ig)G and IgM levels were elevated in patients with a more severe disease course. This increased baseline antibody response however was associated with decreased odds for hospital mortality. Levels of the pro-inflammatory cytokines IL-6, IP-10 and IL-8, the anti-inflammatory cytokine IL-10 and the antiviral cytokines IFN-α, IFN-β and IFN-λ1 were increased with disease severity. Remarkably, we found significantly lower levels of IFN-λ2,3 in critically ill patients compared to patients of the moderate and severe disease category. Finally, levels of IL-8, IL-6, IP-10, IL-10, IFN-α, IFN-β, IFN-γ and IFN-λ1 at baseline were positively associated with mortality, whereas higher IFN-λ2,3 levels were negatively associated with mortality.
format Online
Article
Text
id pubmed-10630327
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106303272023-11-07 Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort Ruytinx, Pieter Vandormael, Patrick Fraussen, Judith Pieters, Zoë Thonissen, Stef Hellings, Niels Stinissen, Piet Callebaut, Ina Penders, Joris Vanhove, Karolien Kieffer, Davy Rummens, Jean-Luc Valkenborgh, Tom Messiaen, Peter Stessel, Björn Mesotten, Dieter Somers, Veerle Sci Rep Article The immune response in patients with Coronavirus Disease 2019 (COVID-19) is highly variable and is linked to disease severity and mortality. However, antibody and cytokine responses in the early disease stage and their association with disease course and outcome are still not completely understood. In this large, multi-centre cohort study, blood samples of 434 Belgian COVID-19 hospitalized patients with different disease severities (ranging from asymptomatic/mild to critically ill) from the first wave of the COVID-19 pandemic were obtained. Baseline antibody and cytokine responses were characterized and associations with several clinical outcome parameters were determined. Anti-spike immunoglobulin (Ig)G and IgM levels were elevated in patients with a more severe disease course. This increased baseline antibody response however was associated with decreased odds for hospital mortality. Levels of the pro-inflammatory cytokines IL-6, IP-10 and IL-8, the anti-inflammatory cytokine IL-10 and the antiviral cytokines IFN-α, IFN-β and IFN-λ1 were increased with disease severity. Remarkably, we found significantly lower levels of IFN-λ2,3 in critically ill patients compared to patients of the moderate and severe disease category. Finally, levels of IL-8, IL-6, IP-10, IL-10, IFN-α, IFN-β, IFN-γ and IFN-λ1 at baseline were positively associated with mortality, whereas higher IFN-λ2,3 levels were negatively associated with mortality. Nature Publishing Group UK 2023-11-07 /pmc/articles/PMC10630327/ /pubmed/37935729 http://dx.doi.org/10.1038/s41598-023-46421-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Ruytinx, Pieter
Vandormael, Patrick
Fraussen, Judith
Pieters, Zoë
Thonissen, Stef
Hellings, Niels
Stinissen, Piet
Callebaut, Ina
Penders, Joris
Vanhove, Karolien
Kieffer, Davy
Rummens, Jean-Luc
Valkenborgh, Tom
Messiaen, Peter
Stessel, Björn
Mesotten, Dieter
Somers, Veerle
Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
title Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
title_full Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
title_fullStr Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
title_full_unstemmed Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
title_short Comprehensive antibody and cytokine profiling in hospitalized COVID-19 patients in relation to clinical outcomes in a large Belgian cohort
title_sort comprehensive antibody and cytokine profiling in hospitalized covid-19 patients in relation to clinical outcomes in a large belgian cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630327/
https://www.ncbi.nlm.nih.gov/pubmed/37935729
http://dx.doi.org/10.1038/s41598-023-46421-4
work_keys_str_mv AT ruytinxpieter comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT vandormaelpatrick comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT fraussenjudith comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT pieterszoe comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT thonissenstef comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT hellingsniels comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT stinissenpiet comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT callebautina comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT pendersjoris comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT vanhovekarolien comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT kiefferdavy comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT rummensjeanluc comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT valkenborghtom comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT messiaenpeter comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT stesselbjorn comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT mesottendieter comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort
AT somersveerle comprehensiveantibodyandcytokineprofilinginhospitalizedcovid19patientsinrelationtoclinicaloutcomesinalargebelgiancohort